Inactivated Vaccine Market - Size, Share, Outlook, and Forecast till 2026

A vaccine that consists of virus particles, bacteria or other pathogens, which were grown in culture and then killed using heat or formaldehyde is called as inactivated vaccine or killed vaccine. The infectivity is reduced, as pathogens for inactivated vaccines are grown under controlled conditions and are killed. Inactivated vaccines are classified into whole virus vaccines, split virus vaccines, and subunit vaccines based on the method of inactivation of virus.

Get Sample copy of research report:

Increasing demand for inactivated vaccines from governments of industrialized and emerging economies is one of the major factors that is expected to drive growth of the global inactivated vaccines market over the forecast period. Moreover, advantages of inactivated vaccines such as safety, stability, and lack of chances of pathogen reactivation over live attenuated vaccines are expected to fuel growth of the global inactivated vaccines market during the forecast period. Rising prevalence of infectious diseases and increasing awareness among people about immunization are other factors propelling the market growth.

However, stringent government regulations and lack of supply of vaccines in remote areas are major factors that are expected to restrain growth of the global inactivated vaccines market.

Get Best Discount on Research Report:

Key Developments in Inactivated Vaccine Market

Key players are adopting various strategies such as mergers, acquisitions, new product launches, expansions, collaborations, partnerships, approvals, and joint ventures to retain its position in the inactivated vaccine market. In 2017, Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, announced its next major advancement in the use of cell-based influenza vaccine technology at its state-of-the art manufacturing facility in Holly Springs, North Carolina.

Moreover, in August 2017, Seqirus launched a new influenza vaccine called FLUAD 1, which is an adjuvanted trivalent influenza vaccine (aTIV) developed to address the burden of influenza in adults aged 65 years and over.

In March 2018, Sanofi completed the acquisition of Bioverativ Inc, a global biotechnology company. Also, Fluzone QIV HD (Quadrivalent Inactivated Influenza Vaccine - High Dose) by Sanofi is currently in phase 111 clinical trial.

Some of the major players operating in the global inactivated vaccine market include Emergent BioSolutions, GlaxoSmithKline plc, Merck & Co., Inc., Seqirus, Sanofi, Valneva SE, Pfizer Inc., and Bharat Biotech among others.

About WMR
Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

Contact Us:
Mr. Shah
Worldwide Market Reports
1001 4th Ave,
#3200
Seattle, WA 98154,
U.S
Tel: +1 415 871 0703

This release was published on openPR.